OverviewSuggest Edit

Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.

TypePrivate
Founded2015
HQBasel, CH
Websitenouscom.com

Latest Updates

Employees (est.) (Jan 2021)27
Cybersecurity ratingBMore

Key People/Management at Nouscom

Riccardo Cortese

Riccardo Cortese

Co-Founder
Marina Udier

Marina Udier

Chief Executive Officer
Stefano Colloca

Stefano Colloca

Chief Technical Officer and Co-Founder
Tiffany Muller

Tiffany Muller

VP Finance
Alfredo Nicosia

Alfredo Nicosia

Co-Founder, Advisor
Cinzia Traboni

Cinzia Traboni

Senior Director of Regulatory Affairs and Co-Founder
Show more

Nouscom Office Locations

Nouscom has offices in Basel and Roma
Basel, CH (HQ)
18 Bäumleingasse
Roma, IT
100 Via di Castel Romano
Show all (2)

Nouscom Financials and Metrics

Summary Metrics

Founding Date

2015

Nouscom total Funding

$62.6 m

Nouscom latest funding size

$49 m

Time since last funding

3 years ago

Nouscom investors

Nouscom's latest funding round in November 2017 was reported to be $49 m. In total, Nouscom has raised $62.6 m
Show all financial metrics

Nouscom Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Nouscom Online and Social Media Presence

Embed Graph

Nouscom News and Updates

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

BASEL, Switzerland, Dec. 11, 2020 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed Göran Ando, MD as the new Chairman of its Board of Directors. Nouscom also appointed...

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

BASEL, Switzerland, July 22, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of new research describing the cutting-edge science and rationale for the design of NOUS-209 and...

Nouscom Strengthens Its Management Team

BASEL, Switzerland, Feb. 26, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed Marina Udier, PhD, as Chief Executive Officer (CEO) and Patricia Delaite, MD, as Chief Medical...

Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland, Dec. 9, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209. In this...

Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug (IND) application for the first clinical trial of its lead candidate NOUS-209 has...

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

BASEL, Switzerland, November 5, 2018 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an...

Nouscom Blogs

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and crosspresentation of locally expressed endogenous tumor antigens…

New viral vectors for infectious diseases and cancer

ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into the current approaches of viral vectored genetic vaccines. In recent years, key improvements to the vacci…

Nouscom Strengthens its Management Team

Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer BASEL, Switzerland – 26. February 2020: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed…

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209. In this first-in-human trial NOUS…

Nouscom will join & present at the SITC 2019

Nouscom will join & present at the SITC 2019 from November 6-10. L'articolo Nouscom will join & present at the SITC 2019 proviene da Nouscom.

Nouscom is presenting at the TMB & Neoantigen Congress

Nouscom will present at the TMB & Neoantigen Congress from October 10-11, 2019 in London. L'articolo Nouscom is presenting at the TMB & Neoantigen Congress proviene da Nouscom.
Show more

Nouscom Frequently Asked Questions

  • When was Nouscom founded?

    Nouscom was founded in 2015.

  • Who are Nouscom key executives?

    Nouscom's key executives are Riccardo Cortese, Marina Udier and Stefano Colloca.

  • How many employees does Nouscom have?

    Nouscom has 27 employees.

  • Who are Nouscom competitors?

    Competitors of Nouscom include Stealth BioTherapeutics, Fauna Bio and Affinia Therapeutics.

  • Where is Nouscom headquarters?

    Nouscom headquarters is located at 18 Bäumleingasse, Basel.

  • Where are Nouscom offices?

    Nouscom has offices in Basel and Roma.

  • How many offices does Nouscom have?

    Nouscom has 2 offices.